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This monograph comprises 16 articles on the state of the science
regarding health risks oftrichloroethylene (TCE) that were sponsored
by the U.S. Environmental Protection Agency (U.S. EPA), the U.S. Air
Force, the U.S. Department of Energy, the National Institute of
Environmental Health Sciences, and the Halogenated Solvents
Industry Alliance in support ofthe U.S. EPA trichloroethylene risk
assessment. TCE, a chlorinated solvent, was widely used for metal
degreasing and is now a common contaminant at Superfund sites and
many Department ofDefense facilities. TCE has been identified in at
least 852 ofthe 1416 sites proposed for inclusion on the U.S. EPA
National Priorities List. Besides being used for degreasing, TCE has
been used as an extractant and as a chemical intermediate. Data on
environmental releases ofTCE are limited. In 1994, 42 million pounds
ofTCE were released into the environment, as reported to the U.S.
EPA Toxic Release Inventory. Most ofthe TCE used in the United
States is released into the atmosphere from vapordegreasing operations.
TCE can enter surface waters via direct discharges or groundwater
through leaching from disposal operations and Superfund sites; the
maximum contaminant level forTCE in drinkingwater is 5 pbb.
These articles comprise the state of the science on issues related
to TCE risk assessment. As part of the publication process, these
articles have undergone peer review by the Environmental Health
Perspectives' editorial board. Staff of the National Center for
Environmental Assessment at the U.S. EPA will use these articles to
write the health risk assessment for TCE, which will include an inte-
grated summary and risk characterization. The updated risk assess-
ment will be peer reviewed by a panel of experts convened by the
U.S. EPA. Comments from the public at large will be a part of this
review. The U.S. EPA staffwill then address these comments with
the goal of making the assessment available in the Integrated Risk
Information System (IRIS) (1), the U.S. EPA database that contains
chemical-specific risk assessment information.
The updated TCE assessment diverges in several respects from the
U.S. EPA assessments published more than 12 years ago. First and
most important, this assessment emphasizes mode-of-action and
pharmacokinetic data to understand and characterize potential non-
cancer and cancer health risks. To facilitate this, we called on several
prominent scientists from both the public and private sectors, many of
whom are actively involved in current research on TCE, to author
papers that discuss the state ofthe science on specific issues important
to risk assessment for TCE. Second, the dose-response assessment
examines newer approaches forevaluating cancer and noncancereffects,
including physiologically based pharmacokinetic and biologically based
dose-response modeling. This includes approaches discussed in the
U.S. EPA revised cancer guidelines, which are changing the ways in
which both cancer and noncancer assessments are performed.
The articles are organized according to three ofthe four elements
ofthe risk assessment paradigm described by the NationalAcademy of
Sciences: hazard identification, dose response, and exposure (2). The
purpose ofhazard identification originally was to identify the adverse
health effects that might be caused by exposure to an agent. "Hazard
identification" has now expanded into "hazard assessment," which
seeks to evaluate the relevance of the experimental information to
human environmental exposure, characterize the conditions leading to
these hazards being expressed in humans, and identifysusceptible pop-
ulations. The TCE assessment emphasizes development ofa mechanis-
tic understanding of both cancer and noncancer health hazards.
Moreover, such data may be used to inform the dose-response assess-
ment. For example, effects identified in the mechanistic pathway
directly related to tumor induction may be judged surrogates for
tumors in the dose-response analysis. The first six articles in this
volume address hazard issues.
Wartenberg and others (3) have reviewed the epidemiologic data.
The best evidence for evaluating potential human carcinogenicity is
derived from epidemiologic studies, and the epidemiologic evidence
on TCE exposure has grown over the past 12 years.
Lash and others (4) describe the pathways for TCE metabolism
and their cross-species relevance. This article also presents rate con-
stants for several ofthe oxidative metabolites based on in vitro assays,
some ofwhich are incorporated into the pharmacokinetic model of
Fisher (5). Lash et al. (4) additionally identify a difference between
sexes in metabolite rates, at least for the glutathione-S-transferase path-
way, which raises questions about susceptibility and sensitive popula-
tions, areas ofincreasing importance in risk assessment.
Pastino and others (6) more thoroughly discuss the issues of
susceptibility and potentially sensitive populations, in addition to
explicitly examining the effects ofTCE exposure to children. In a
1994 report Science andJudgment in Risk Assessment, the National
Academy ofSciences (7) emphasized the need to identify, character-
ize, and include susceptible populations in risk assessment studies.
Risks to children received increasing attention after the 1993 National
Research Council report on Pesticides in the Diets ofInfants and
Children (8). The article by Pastino et al. (6) starts this discussion.
TCE has produced an elevated incidence oftumors in rodents in
bioassays by both the oral and inhalation routes ofexposure. Articles
by Moore and Harrington-Brock (9), Bull (10), Lash et al. (11), and
Green (12) discuss mode-of-action hypotheses for organ-specific
tumors. Mode-of-action data have the potential to refine science pol-
icy defaults on cross-species scaling and dose-response approaches.
Although TCE is a well-studied chemical, the data currently available
are considered "mode ofaction" rather than "mechanism ofaction"
where a detailed understanding ofcritical events has been identified.
This article is part of the monograph on Trichloroethylene Toxicity.
Address correspondence to C.S. Scott, National Center for Environmental
Assessment, Mail Code 8623D, U.S. EPA, Washington, DC 20460. Telephone: (202)
564-3286. Fax: (202) 565-0079. E-mail: scott.cheryl@epa.gov
The views in this and the following articles are those of the authors and do not
necessarily reflect the views or policies of the U.S. Environmental Protection Agency.
Received 20 October 1999; accepted 27 October 1999.
Environmental Health Perspectives * Vol 108, Supplement 2 * May 2000 159SCOTT AND COGLIANO
Moore and Harrington-Brock (9) do not adopt a traditional review
ofthe mutagenicity data on TCE and its metabolites but instead raise
several issues regarding the interpretation ofmutagenicity and genetic
toxicity tests in shedding light on whether these processes are key events
in tumor initiation. As discussed in the U.S. EPA proposed cancer
guidelines, a salient question is whether TCE or its metabolites interacts
directly with and mutates DNA to bring about changes in gene expres-
sion orwhether DNA mutation is achieved through some other process.
TheMoore and Harrington-Brockartide examines this question.
Bull (10), Lash et al. (11), and Green (12) present the experimental
support for several modes ofaction for tumor development in rodents.
These articles discuss a number ofhypotheses including the influence
on tumor development from mutagenesis, cytotoxicity, cell prolifera-
tion, X2u~-globin, peroxisome proliferation, oxidative stress, receptor
binding, and perturbation ofcell-signaling pathways.
Quantitative dose-response issues important to the statistical
modeling of both noncarcinogenic and carcinogenic effects are dis-
cussed in articles by Fisher (5), Bois (13), Clewell et al. (14), Bois
(15), Boyes et al. (16), Barton and Clewell (17), Chen (18), and
Rhomberg (19). Because pharmacokinetic data are available for the
TCE assessment, dose metrics other than applied dose may be evalu-
ated in benchmark and other dose-response analyses.
Fisher's article (5) describes modeling liver concentration ofTCE
and its oxidative metabolites, while Clewell et al. (14) model plasma
concentrations ofthe oxidative metabolites and flux through the kidney
for metabolites ofthe glutathione-S-transferase pathway. Both models
are scaled from mice or rats to humans and provide estimates ofhuman
equivalent doses simulating inhalation and oral exposure routes.
Parameters from these models have been further subjected to an
uncertainty analysis in the articles by Bois (13,15). The application of
Baysian statistical methods is increasingly used for updating estimates
ofpharmacokinetic model parameters. Moreover, these analyses can
provide an additional set ofdosimetric estimates that in some instances
are very different from those obtained with the original model. These
findings make the risk assessor's job more complex.
Boyes and others (16) test whether Haber's Law or a dose metric
that integrates time and concentration best describes neurologic effects
with high-level TCE exposure.
Barton and Clewell (17) examine both experimental and pharmaco-
kinetically derived dose metrics in their analysis ofneurologic and sys-
temic organ toxicity seen in the rodent studies. The article further
applies benchmark dose methodology to the quantitative analysis of
these effects.
The U.S. EPA proposed cancer guidelines recommend that dose-
response modeling be carried out in two parts: analysis ofthe curve
shape within the range ofthe data and extrapolation below the observ-
able data. Application ofa biologically based model is preferred for
evaluating the dose-response relationship for carcinogenic effects.
Such an approach is described in the article by Chen (18), which
explores the relationship between TCE and two of its oxidative
metabolites, dichloroacetic acid and trichloroacetic acid, under the
hypothesis that these chemicals induce liver tumors in mice through
promotion of preexisting initiated cells. Unfortunately, the data
necessary for supporting a biologically based model are not robust and
default dose-response approaches also need to be employed.
Rhomberg (19) presents a comprehensive analysis of the liver,
lung, and kidney tumor data and pharmacokinetic model-derived dose
metrics using default dose-response approaches. Not only does the
analysis provide a choice ofdose metrics from the two pharmacoki-
netic models and their uncertainty analyses, which yields four esti-
mates for a single dose metric, it also examines the influence ofseveral
metabolites of the cytochrome P450 and glutathione-S-transferase
pathways. This leads to an examination ofthe TCE-liver tumor rela-
tionship, for example, from multiple perspectives. Finally, Rhomberg
attempts to reconcile influences of route ofadministration on tumor
incidence in the inhalation and gavage bioassays by examining
systemic and organ-specific dose metrics.
The last article in this series, by Wu and others (20), identifies
sources, pathways, and routes of exposure as well as enumerates
exposed populations. In addition to an examination ofTCE, this
studyexamines exposure to the principal metabolites ofTCE as well as
to other parent compounds that have these as metabolites. It is impor-
tant to assess background exposure to these compounds as well as how
TCE exposure adds to this background.
These articles represent the state of the science for TCE. The
challenge ahead for the staffofthe National Center for Environmental
Assessment is to synthesize the information from these studies to
develop the riskcharacterization forTCE.
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